Showing posts with label Chairman. Show all posts
Showing posts with label Chairman. Show all posts

Wednesday, July 14, 2010

The El-Hibri Foundation Launches Website

Fuad El-Hibri awards the 2009 Peace Education award

The El-Hibri Foundation is a nonprofit organization with the goal of fostering dialogue between various religions and encouraging nonviolent solutions to global challenges affecting humankind. The Foundation has a new website at www.elhibrifoundation.org.

The Foundation, lead by Chairman of the Board of Trustees Fuad El-HIbri, is divided into four different initiatives: The Peace Education Initiative, The Interfaith Dialogue Initiative, The Humanitarian Aid Initiative, and The Social Justice Initiative.

The Peace Education Initiative focuses on conflict resolution, embracing cultural diversity, and supporting cross-cultural approaches to peace-building. The Interfaith Dialogue Initiative focuses on supporting understanding between the three Abrahamic faiths: Islam, Judaism and Christianity. The Humanitarian Aid Initiative provides grants to organizations that aim at delivering education and medical care to the disadvantaged. The last of the four initiatives is the Social Justice Initiative. The Social Justice Initiative addresses issues of equality, justice and human rights, especially for women and children.

The El-Hibri Foundation promotes these four initiatives through the provision of grants. Since its creation in 2001, the Foundation has given away 36 grants totaling over 8.2 million dollars.

For more information on the El-Hibri Foundation visit their website: www.elhibrifoundation.org


Friday, August 14, 2009

Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript

Emergent BioSolutions Inc., (EBS)

Q2 2009 Earnings Call

August 6, 2009 5:00 pm ET

Executives

Robert G. Burrows - Vice President, Investor Relations

Fuad El-Hibri - Chairman of the Board, Chief Executive Officer

R. Don Elsey - Chief Financial Officer

Daniel J. Abdun-Nabi - President, Chief Operating Officer

W. James Jackson, Ph.D. - Senior Vice President and Chief Scientific Officer

Analysts

Eric Schmidt - Cowen & Company

David Moskowitz - Caris & Company

Mona Ashiya - J.P. Morgan

Sean Long – Kennedy Capital Management

Presentation

Operator

Welcome to the Emergent BioSolutions Incorporated second quarter 2009 financial results conference call. (Operator Instructions) I would now like to turn the call over to Mr. Robert Burrows.

Robert Burrows

Good afternoon ladies and gentlemen. My name is Robert Burrows, Vice President of Investor Relations for Emergent. Thank you for joining us today as we discuss Emergent BioSolutions financial results for the second quarter and first six months of 2009. As is customary, our call today is open to all participants. In addition, the call is being recorded and is copyrighted by Emergent BioSolutions.

Joining me on the call this afternoon will be Fuad El-Hibri, Chairman and Chief Executive Officer, and Don Elsey, Chief Financial Officer. Additional members of our senior management team will be present on the call for purposes of the Q&A session.

Before we begin, however, I am compelled to remind everyone that during the all management may make projections and other forward-looking statements regarding future events and the company’s prospects or future performance. These forward-looking statements reflect Emergent’s current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve substantial risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements.

You are encouraged to review Emergent’s filings with the SEC on Forms 10-K, 10-Q, and 8-K for more information on the risks and uncertainties that could cause actual results to differ.

Thursday, August 6, 2009

Fuad El-Hibri on Yotify

user image - profile
  • Yotify since: 06/18/2009

Fuad El-Hibri on Corridor Inc.

Fuad El-Hibri, chairman and chief executive officer at Emergent BioSolutions Inc., is a finalist for the Ernst & Young Entrepreneur of the Year® 2009 Award in the Greater Washington region. The awards program recognizes extraordinary innovation, financial performance and personal commitment to a businesses and its community. Emergent BioSolutions, based in Rockville, is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics....

Fuad El-Hibri On Lead411

Description: Fuad El-Hibri is Emergent BioSolutions's CEO/Chairman. With a Lead411 subscription you are able to view the email addresses ( @emergentbiosolutions.com ) of the executives. Besides e-mail, other employee info could include phone, biography, education, and extension. Management titles include VP, Chief, Vice President, managers, & more. Similar last names to El-Hibri can be found at Executive Directory - El-Hibri.

BIOGRAPHY:
Mr. Fuad El-Hibri is the Chairman and Chief Executive Officer of Emergent BioSolutions Inc. (Emergent), a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and therapeutics to prevent and treat life-threatening diseases. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only FDA-licensed vaccine for pre-exposure prophylaxis of anthrax disease. The company is also investing heavily in the development of a broad pipeline of products that address specific global unmet medical needs, including Typhoid, Tuberculosis, Hepatitis B and Chlamydia.

Mr. El-Hibri has extensive experience in the biopharmaceutical industry beginning with Porton Products, Ltd. (Porton), a mid-sized biotechnology company in the United Kingdom. Subsequent to the successful marketing and distribution of Porton’s biodefense vaccines to foreign governments in the early 1990’s, Mr. El-Hibri organized a management buyout of Porton in 1994, forming Speywood Holdings, Ltd. He was appointed to the Board of Directors of Speywood Holdings, Ltd. and acted as an advisor to the senior management team in the operations of the company until 1996.

Emergent BioSolutions hands out bonuses

Emergent BioSolutions hands out bonuses

Bonus may be a bad word right now — but not for a biotech that is actually making money.

Alongside minimal pay raises, execs received bonuses in 2008 that increased anywhere from 5 percent to 43 percent from their 2007 bonuses. Fuad El-Hibri got the lowest increase, but the highest bonus at $323,250. The highest increase was doled out to Kyle Keese, who took home a $96,460 bonus for 2008.

Though, at least one manager’s perk wasn’t quite so perky last year. Robert Kramer, who stepped down in January as head of Emergent’s manufacturing subsidiary and instead will manage a contract that the company hopes to nail with the federal Government year, got a 48 percent decrease in his bonus from 2007, bringing his 2008 figure to $78,815…